Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5427]
News [12613]
Articles [172]
Editorials [5]
Conferences [246]
elearning [17]
Comment on 'Ovarian Cancer: An ESMO Guide for Patients'
Dr Nicoletta Colombo - Istituto Europeo di Oncologia, Milan, Italy
Comment on 'Ovarian Cancer: An ESMO Guide for Patients' ( Dr Nicoletta Colombo - Istituto Europeo di Oncologia, Milan, Italy )
1 Nov 2018
ILLUMINATE 301: ipilimumab versus IMO-2125 combined with ipilimumab in anti PD...
Prof Paolo Ascierto - Istituto Nazionale Tumori, Milan, Italy
ILLUMINATE 301: ipilimumab versus IMO-2125 combined with ipilimumab in anti PD 1 refractory melanoma ( Prof Paolo Ascierto - Istituto Nazionale Tumori, Milan, Italy )
29 Oct 2018
Dosing regiment in the combination of ipilimumab and nivolumab in stage III...
Dr Lisette Rozeman - Netherlands Cancer Institute, Amsterdam, Netherlands
Dosing regiment in the combination of ipilimumab and nivolumab in stage III melanoma ( Dr Lisette Rozeman - Netherlands Cancer Institute, Amsterdam, Netherlands )
29 Oct 2018
COLUMBUS: Encorafenib plus binimetinib versus vemurafenib or encorafenib in...
Prof Dirk Schadendorf - Uniklinik Essen, Essen, Germany
COLUMBUS: Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma ( Prof Dirk Schadendorf - Uniklinik Essen, Essen, Germany )
29 Oct 2018
Latest advances in treatment for ALK positive NSCLC
Prof Gordon McVie, Dr Lázaro Quintela
Latest advances in treatment for ALK positive NSCLC ( Prof Gordon McVie, Dr Lázaro Quintela )
26 Oct 2018
The case for biosimilars
Dr Hans-Christian Kolberg - Marienhospital, Bottrop, Germany
The case for biosimilars ( Dr Hans-Christian Kolberg - Marienhospital, Bottrop, Germany )
26 Oct 2018
Highlights in early non-metastatic NSCLC and thoracic tumours
Dr Enriqueta Felip - Vall d'Hebron University Hospital (VHIO), Barcelona, Spain
Highlights in early non-metastatic NSCLC and thoracic tumours ( Dr Enriqueta Felip - Vall d'Hebron University Hospital (VHIO), Barcelona, Spain )
26 Oct 2018
Anti–PD-L1 atezolizumab or chemotherapy as second-line therapy in patients with...
Prof Jean-Louis Pujol - CHRU de Montpellier, Hôpital Arnaud de Villeneuve...
Anti–PD-L1 atezolizumab or chemotherapy as second-line therapy in patients with SCLC ( Prof Jean-Louis Pujol - CHRU de Montpellier, Hôpital Arnaud de Villeneuve, Montpellier, France )
26 Oct 2018
Combination strategies of immunotherapy in breast cancer
Prof Guiseppe Curigliano - European Institute of Oncology, Milan, Italy
Combination strategies of immunotherapy in breast cancer ( Prof Guiseppe Curigliano - European Institute of Oncology, Milan, Italy )
26 Oct 2018
Highlights in SCLC from ESMO 2018
Dr Noemi Reguart - University of Barcelona, Barcelona, Spain
Highlights in SCLC from ESMO 2018 ( Dr Noemi Reguart - University of Barcelona, Barcelona, Spain )
26 Oct 2018
ABOUND.sqm: nab-paclitaxel and carboplatin induction followed by nab-paclitaxel...
Dr David R. Spigel - Tennessee Oncology, Nashville, USA
ABOUND.sqm: nab-paclitaxel and carboplatin induction followed by nab-paclitaxel maintenance in NSCLC ( Dr David R. Spigel - Tennessee Oncology, Nashville, USA )
26 Oct 2018
Safety analysis of entrectinib for NTRK fusion tumours
Dr George D. Demetri - Harvard Cancer Center, Boston, USA
Safety analysis of entrectinib for NTRK fusion tumours ( Dr George D. Demetri - Harvard Cancer Center, Boston, USA )
26 Oct 2018

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation